CEO Mark Erlander is scheduled to present today at the H.C. Wainwright Global Investment Conference, marking the company’s third major investor event this week. This appearance follows recent presentations at conferences hosted by Wells Fargo and Morgan Stanley, demonstrating a concerted effort to engage with the investment community.
Financial Position and Clinical Pipeline
The company maintains a solid financial foundation with approximately $71 million in cash and short-term investments. During the second quarter, the monthly cash burn rate averaged $8.3 million. Based on these figures, Cardiff Oncology’s current liquidity is projected to fund operations through the first quarter of 2027, providing substantial runway to advance its clinical development programs.
At the core of the company’s value proposition is Onvansertib, a PLK1 inhibitor that represents Cardiff Oncology’s primary clinical asset. The drug candidate is currently under investigation across multiple cancer indications:
- RAS-mutant mCRC: The Phase 2 CRDF-004 trial demonstrated a 49% response rate compared to 30% in the control group
- Metastatic Breast Cancer: A 40% response rate was observed in combination therapy for metastatic triple-negative breast cancer (mTNBC)
- Pancreatic Cancer and Lung Cancer: Additional studies are currently underway
The company recently strengthened its intellectual property position with the granting of a second patent for mCRC treatment, providing protection until at least 2043.
Should investors sell immediately? Or is it worth buying Cardiff Oncology?
Technical Analysis Shows Bearish Pressure
Despite increased investor attention from the presentation schedule, Cardiff Oncology’s stock has exhibited significant volatility recently. Shares gained 2.76% to close at $2.23 yesterday but traded within a 6.07% range during the session. Technical indicators remain predominantly bearish, with three out of four moving averages continuing to signal downward momentum.
Key resistance levels are established at $2.42 and $2.60, while support appears at $1.84 and $1.66. Notably elevated trading volumes suggest growing market interest, though whether this activity will translate into a sustained trend reversal remains uncertain.
Investors are closely watching whether this series of presentations will attract new capital and potentially reverse the current negative trend.
Ad
Cardiff Oncology Stock: Buy or Sell?! New Cardiff Oncology Analysis from September 9 delivers the answer:
The latest Cardiff Oncology figures speak for themselves: Urgent action needed for Cardiff Oncology investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from September 9.
Cardiff Oncology: Buy or sell? Read more here...
